ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0889

Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis

Ziyuan He1, Marla Glass1, Pravina Venkatesan2, Alexandra Ferrannini3, Marie Feser4, Christy Bennett1, David Boyle5, Kristen Demoruelle6, Kristine Kuhn7, Fan Zhang8, Thomas Bumol9, Ananda Goldrath3, Peter Skene3, V. Michael Holers10, Xiaojun Li1, Adam Savage1, Gary Firestein11, Kevin Deane12, Troy Torgerson13 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2Allen Insitute, Seattle, WA, 3Allen Institute for Immunology, Seattle, 4University of Colorado Anschutz Medical Campus, Aurora, CO, 5UCSD, La Jolla, CA, 6University of Colorado Anschutz Medical Campus, Golden, CO, 72022 - 2023 / Adult/ University of Colorado, Aurora, CO, 8The University of Colorado, Aurora, CO, 9Allen Institute for Immunology, San Diego, CA, 10University of Colorado, Denver, CO, 11University of California, San Diego, San Diego, CA, 12University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 13Allen Institute for Immunology, Enumclaw, WA

Meeting: ACR Convergence 2025

Keywords: CCP, Genomics and Proteomics, Inflammation, rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (0885–0890)

Session Type: Abstract Session

Session Time: 11:00AM-11:15AM

Background/Purpose: Prior to the onset of clinically apparent inflammatory arthritis (IA)/synovitis (clinical RA), ACPA+ ‘at-risk’ individuals (ARI) show alterations in the abundance of effector T cell subsets in the peripheral circulation. However, it remains unclear which T cell subsets define the progression to clinical RA. A population of central memory CD4 T cells expanded over time as ACPA+ ARI progressed to clinical RA (termed ‘converters’). In this study, we investigated the molecular phenotype of this expanding memory T cell population in converters.

Methods: We conducted a longitudinal analysis of peripheral blood mononuclear cell (PBMC) transcriptomes obtained by scRNA-seq. We performed linear mixed effects longitudinal modeling on samples from ACPA+ participants over a period of 2 years prior to the onset of clinical RA (n=13 converters; n=61 samples; mean 4.7 samples per converter; Table 1). These samples were from a prospective longitudinal cohort study of ACPA+ individuals without baseline IA/synovitis. Cell-cell communication analyses to infer ligand-receptor interactions and downstream gene expression changes were performed using Liana and NicheNet.

Results: A memory CD4 T cell population that expanded almost 2-fold over time from baseline to conversion (FDR< 0.05) expressed PD1, ICOS, CXCR5 and KLRB1 transcripts, exhibited a transcriptionally activated state (P< 0.05) and were enriched for a published transcriptional signature of Tfh/Tph cells from RA synovial tissue (P< 0.01; Zhang 2019 Nature Immunol). Using an independent trimodal single cell validation dataset (Thomson 2023 Nature Immunol), we identified a CD4 memory population that expressed a similar PD1+ ICOS+ CXCR5+ KLRB1+ transcriptional signature. Notably, this population had the highest surface protein expression of PD-1 and ICOS, along with high expression of KLRB1 protein. We inferred key receptor-ligand communication between two lymphocyte populations that expanded as converters progressed to clinical RA: (1) the memory CD4 T cell population; and (2) CD27- TBX21+ atypical B cells. Potential receptor-ligand complexes included CD40LG-CD40, CD86-CD28, and SEMA4D-CD72, and was supported by downstream changes in gene expression following receptor-ligand interactions reported in both these populations.

Conclusion: These results suggest the increased population of central memory CD4 T cells in the peripheral blood of converters approaching transition to clinical RA is associated with changes in activated T cells with a B cell helper phenotype. This memory population could be similar to Tph cells found to be clonally expanded in RA synovium, but also shares features of Th17 cells, suggesting they could produce pro-inflammatory mediators that participate in disease pathogenesis. These findings are supported by inferred bidirectional signaling between these memory CD4 T cells and atypical B cells during progression to clinical RA. Our findings provide key insights into adaptive immune mechanisms that contribute to the progression from an at-risk state to clinical RA, and may suggest targets for early preventive intervention or biomarkers for RA prevention trials.

Supporting image 1


Disclosures: Z. He: None; M. Glass: None; P. Venkatesan: None; A. Ferrannini: None; M. Feser: None; C. Bennett: Adaptive Biotechnologies, 11, Eli Lilly, 5; D. Boyle: None; K. Demoruelle: Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, Gilead, 5, Merck/MSD, 2, Pfizer, 5; K. Kuhn: Solarea, 2; F. Zhang: None; T. Bumol: Tentarix Biotherapeutics, 4; A. Goldrath: Arsenal Bio, 1, Foundery Innovations, 1; P. Skene: None; V. Holers: None; X. Li: Eli Lilly, 5; A. Savage: None; G. Firestein: Eli Lilly, 5; K. Deane: Inova Diagnostics, 1; T. Torgerson: Eli Lilly, 2, Pharming Healthcare, 2, Takeda, 2; M. Gillespie: Novo Nordisk, 11, Omeros, 11.

To cite this abstract in AMA style:

He Z, Glass M, Venkatesan P, Ferrannini A, Feser M, Bennett C, Boyle D, Demoruelle K, Kuhn K, Zhang F, Bumol T, Goldrath A, Skene P, Holers V, Li X, Savage A, Firestein G, Deane K, Torgerson T, Gillespie M. Potentially pathogenic memory CD4 T cells with a B cell helper phenotype expand in ACPA+ individuals during progression to rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/potentially-pathogenic-memory-cd4-t-cells-with-a-b-cell-helper-phenotype-expand-in-acpa-individuals-during-progression-to-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/potentially-pathogenic-memory-cd4-t-cells-with-a-b-cell-helper-phenotype-expand-in-acpa-individuals-during-progression-to-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology